Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Update

Ipsen S.A. (OTCMKTS:IPSEY) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,000 shares, a growth of 100.0% from the March 31st total of 500 shares. Based on an average daily volume of 4,200 shares, the days-to-cover ratio is currently 0.2 days.

Ipsen Stock Up 0.7 %

Shares of IPSEY stock traded up $0.20 during trading hours on Friday, reaching $30.36. 549 shares of the stock traded hands, compared to its average volume of 2,160. Ipsen has a 1-year low of $26.97 and a 1-year high of $34.34. The business has a fifty day moving average price of $29.01 and a 200 day moving average price of $29.03.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.